H-Cov-Run: HDL Target of CoViD19 ? Analysis on the Caregivers of the Reunion University Hospital
Study Details
Study Description
Brief Summary
Since December 2019, the Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) pandemic has spread around the world. The people most exposed to this virus remain the healthcare personnel who are on the front line in the fight against this pandemic. Due to the delayed nature of the pandemic in Reunion island and its insular geographical situation, the study of the voluntary medical personnel will allow the investigators to establish a longitudinal follow-up of the anomalies of the lipidic balance in relation to the exposure to the SARS-Cov virus. 2. During bacterial infections, the lipid profiles are profoundly modified with very significant reductions in plasma cholesterol levels, LDL-C but especially HDL-C whose concentrations are particularly low. Lipid profiles are altered during viral infections, for example, the severity of dengue is inversely correlated with total cholesterol and LDL-C but not with HDL-C levels, according to a recent meta-analysis. The hepatitis C virus circulates in serum linked to lipoproteins rich in triglycerides and HDL can facilitate its entry into cells via Scavenger receptor class B type 1 (SRB1). Likewise, it has been shown that apoA1 can bind to the dengue virus and increase its infectivity by promoting its entry into cells, also via SRB1. At the moment, nothing is known about the lipid profiles in subjects with SARS-CoV-2. The investigator hypothesize that a drop in plasma HDL-C levels and a change in their size during infection could justify future therapeutic approaches aimed at supplementing the subjects most at risk of pulmonary complications. In a model of Pseudomonas aeruginosa pneumonia in mice, investigators have shown that the injection of reconstituted HDL allowed to limit the pulmonary inflammation and the deleterious consequences of the infection. The investigator propose to study not only the lipid profiles in subjects who are infected with SARS-CoV-2 but also the polymorphisms of genes involved in the regulation of lipoprotein levels like that of Cholesterol Ester-Transfer Protein (CETP) depending on the developed forms, symptomatic or not.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| caregivers caregivers |
Other: research specific blood sample
one blood sample before the epidemic phase
one blood sample during epidemic phase
one blood sample after epidemic phase
|
Outcome Measures
Primary Outcome Measures
- Change of lipid profile during exposure to SARS-Cov-2 [at the end of the study, maximum 1 year]
lipid profile
Secondary Outcome Measures
- HDL-cholesterol size [at the end of the study, maximum 1 year]
HDL-cholesterol size
- circulating plasma cytokine levels [at the end of the study, maximum 1 year]
circulating plasma cytokine levels
- ACE2 gene polymorphisms [at the end of the study, maximum 1 year]
ACE2 gene polymorphisms
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Caregiver in Reunion island University Hospital Center
-
Practicing in a care service possibly exposed to the coronavirus
-
Signed Consent
Exclusion Criteria:
-
Refusal to participate
-
Already infected by Covid19
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Centre Hospitalier Universitaire Réunion | Saint-Denis | France | 97400 | |
| 2 | Centre Hospitalier Universitaire de la Réunion | Saint-Pierre | France | 97448 |
Sponsors and Collaborators
- Centre Hospitalier Universitaire de la Réunion
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 2020/CHU/08